Lipopolysaccharide-Targeted Peptide Mimic Vaccine Against Q Fever
AssigneeThe Curators of the University of Missouri
InventorGUOQUAN ZHANG
Life of this patent
Estimating the term…
Abstract
A vaccine and method of vaccination for conferring immunity to Q fever is described. The vaccine comprises a polypeptide with a sequence of SLTWHKHELHRK (m1E41920) or SPPWHKHELHRK (m1E44), or at least 90% identity to m1E41920 or m1E44. Constructs are also provided for use in vaccination and treatment of Q fever. A method to identify and generate new vaccines to prevent diseases caused by intracellular Gram-negative bacteria is also described.
Claims13
An isolated humanized antibody or antigen-binding fragment thereof for protection against gram negative intracellular bacterial infection, that specifically binds to a lipopolysaccharide-based epitope in gram negative bacteria, wherein the humanized antibody or antigen-binding fragment thereof competes for binding to a lipopolysaccharide-based peptide mimetic sequence of SLTWHKHELHRK (SEQ ID NO:
- 7) or SPPWHKHELHRK (SEQ ID NO:
- 8), or a peptide sequence having at least 90% identity to SLTWHKHELHRK (SEQ ID NO:
- 7) or SPPWHKHELHRK (SEQ ID NO:
- 8), or pharmaceutically acceptable salt thereof.
A method of identifying a protective lipopolysaccharide-based peptide mimetic for protection against a specific lipopolysaccharide-based infection of gram negative intracellular bacteria in a subject;
- the method comprising:
- generating a protective monoclonal antibody specific to a lipolysaccharide-based epitope of a specific intracellular Gram-negative bacteria that causes the specific LPS-based intracellular Gram-negative bacterial infection in the subject;
- screening a Phage Display Library with a protective monoclonal antibody specific to the lipolysaccharide-based epitope of a specific intracellular Gram-negative bacteria;
- identifying one or more mimetic peptides from the phage display library that mimic the protective epitope of lipopolysaccharide;
- and
- evaluating the protective efficacy of the one or more mimetic peptides to identify the one or more mimetic peptides that confer an effective protective antigen against the specific LPS-based intracellular Gram-negative bacterial infection in the subject.
Dependencies are inferred from the claim text.